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Abstract The citalopram for Alzheimer’s disease trial
evaluated citalopram for the management for agitation in
Alzheimer’s disease patients. Sparse data was available
from this elderly patient population. A nonlinear mixed
effects population pharmacokinetic modeling approach was
used to describe the pharmacokinetics of R- and S-citalo-
pram and their primary metabolite (desmethylcitalopram).
A structural model with 4 compartments (one compart-
ment/compound) with linear oral absorption and elimina-
tion described the data adequately. Overall, the model
showed that clearance of the R-enantiomer was slower than
the clearance of the S-enantiomer. Without accounting for
any patient-specific covariates, the population estimate of
the metabolic clearance of citalopram was 8.6 (R-citalo-
pram) and 14 L/h (S-citalopram). The population estimate
of the clearance of desmethylcitalopram was 23.8 (R-Dcit)
and 38.5 L/h (S-Dcit). Several patient-specific covariates
were found to have a significant effect on the pharma-
cokinetics of R,S-citalopram and desmethylcitalopram. A
significant difference in the metabolic clearance of R-ci-
talopram between males and females (13 vs 9.05 L/h) was
identified in this analysis. Both R- and S-citalopram
metabolic clearance decreased with age. Additionally,
consistent with literature reports S-citalopram metabolic
clearance increased with increasing body weight and was
significantly influenced by CYPC19 genotype, with a dif-
ference of 5.8 L/h between extensive/rapid and
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intermediate/poor metabolizers. R,S-desmethylcitalopram
clearance increased with increasing body weight. This
model may allow for the opportunity to delineate the effect
of R- and S-citalopram on pharmacodynamics outcomes
related to the management of agitation in Alzheimer’s
disease.
Keywords Citalopram  Pharmacokinetics  Agitation 
Alzheimer’s disease
Introduction
Patients with dementia, including those with Alzheimer’s
disease (AD), often suffer from agitation [1]. Symptoms of
agitation include restlessness, tumultuous emotions and
violent/excessive movements [2]. There is no approved FDA
pharmacological intervention for the management of agita-
tion in patients with AD [3]. Nonetheless, several drug
classes are used to manage agitation in AD patients including
antipsychotics, anticonvulsants and antidepressants [2, 3].
A recent multi-center, randomized, placebo-controlled,
double-blind, parallel group trial, The Citalopram in Alz-
heimer’s disease (CitAD) study, evaluated the efficacy of
citalopram for the management of agitation in AD patients
[4]. The dose of citalopram was set to a target of
30 mg/daily, with dose adjustment possible based on
response and tolerability. Overall the study showed that
patients who received citalopram improved compared with
the placebo group on agitation outcomes. However, wors-
ening of cognition and QTc prolongation was observed in
the citalopram group [4, 5].
Citalopram, a selective serotonin reuptake inhibitor
(SSRI), is a racemic mixture composed of 50 % (R)-(-)-
citalopram and 50 % (S)-(?)-citalopram. It has been sug-
gested that most of the antidepressant effects are
attributable to S-citalopram [6, 7]. This is further supported
by studies showing that S-citalopram (a.k.a., escitalopram)
alone exerts better efficacy than racemic citalopram for
depression [8–11]. Citalopram is readily absorbed after oral
administration and has a bioavailability of approximately
80 %, a volume of distribution of 12–16 L/kg, and an
elimination half-life in healthy adults of 30–35 h [12, 13].
It is metabolized by liver cytochrome P450 enzymes (CYP
2C19, 2D6 and 3A4) to its major metabolite desmethylci-
talopram, which undergoes further demethylation mediated
by CYP2D6, to form didemethylcitalopram [12, 13]. The
systemic clearance of citalopram decreases with age due to
a decrease in metabolic activity [14], with the elimination
half-life approximately 30 % longer in the healthy elderly
population compared to a young population [15]. Previ-
ously published population pharmacokinetic models for
citalopram and S-citalopram have also shown decreased
clearance of the drug with increasing age [16, 17].
Due to the sparse sampling approach utilized in most
studies of elderly people it is difficult to perform a classical
pharmacokinetic analysis, which requires extensive sam-
pling. Population mixed effects pharmacokinetic models are
widely used as a tool to describe pharmacokinetics and
explore exposure–response relationships in drug develop-
ment [18]. The advantage of a population pharmacokinetic
approach is that it can leverage the sparse data available in
order to make inferences about population and individual
level pharmacokinetics. As the objective of the CitAD trial
was to assess the efficacy and side effects of citalopram for
the management of agitation in AD patients, understanding
the pharmacokinetics of citalopram in this elderly patient
population is key towards establishing an exposure–response
relationship. This in turn is critical towards establishing the
effectiveness of citalopram as a therapeutic agent for man-
agement of agitation in this patient population.
The objective of this study was to use mixed effects
population pharmacokinetic modeling approach to describe
the pharmacokinetics of R,S-citalopram and their primary
metabolites (R,S-desmethylcitalopram) and identify
patient-specific covariates that contribute to the variability
in pharmacokinetics parameters. The effect of age, weight,
sex and CYP2C19 genotype on the pharmacokinetics
parameters of the parent and metabolite of both enan-




Ninety-four patients from the CitAD study received citalo-
pram. A starting dose of 10 mg was titrated up over 2 weeks
to the target of 30 mg daily, provided as a single dose in the
morning of three capsules each containing 10 mg. Plasma
samples were collected at weeks 3, 6, and 9. R,S-citalopram
and R,S-desmethylcitalopram concentrations were deter-
mined using a sensitive high-performance liquid chro-
matography method (HPLC) with a chiral column with UV
detection [19, 20]. Figure 1 illustrates the sampling design
by showing the number of plasma samples versus time after
dose. Scatter plots of concentration versus time after dose
stratified per enantiomer (Fig. 2) show the spread of plasma
concentrations of each compound after dose. The limit of
quantitation for each enantiomer was 5 ng/mL except for
S-desmethylcitalopram where the limit was 10 ng/mL. More
detailed information about the CitAD trial design can be
found in previously published reports [4, 5].
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Population pharmacokinetic model development
Base model
A step-wise approach was adopted to build a joint model
for both citalopram enantiomers and their primary
metabolites (desmethylcitalopram). In this approach a
model was built for R-citalopram parent followed by the
addition of its metabolite. Similarly a parent-metabolite
model was built for S-citalopram. The two models were
then combined into one model describing the pharma-
cokinetics of R,S-citalopram and their two primary
metabolites. Nonlinear mixed effects modeling was per-
formed using NONMEM 7.1 (ICON Software Develop-
ment). The model was developed using ordinary
differential equations implemented in NONMEM as



























 C 2ð Þ  CLSm
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where C(1) is the concentrations of R-citalopram, C(2) is
the concentrations of S-citalopram, C(3) is the concentra-
tion of R-desmethylcitalopram and C(4) is the concentra-
tion of S-desmethylcitalopram. Ka is the absorption rate
constant. CLRp and CLSp are the apparent metabolic
clearance of R,S-citalopram. CLRm and CLSm are the
apparent clearance of R,S-desmethylcitalopram. VR and VS
are the apparent volume of distributions for the two
enantiomers.
Based on previously published population pharmacoki-
netic models for Citalopram [16, 17], a one-compartment
model with first order absorption and elimination was
implemented for the parent compounds. A two-compart-
ment model for the R- and S-citalopram was also tested.
One and two-compartment models were then evaluated for
the metabolite. Additionally, two assumptions for clear-
ance were evaluated: either clearance allowed from parent
and metabolite compartments (partial parent to metabolite
conversion) or clearance allowed only from the parent to
the metabolite compartment (complete parent to metabolite
conversion). Direct dosing into the metabolite compart-
ments was also evaluated. A statistical model was also
included to describe the between subject variability (BSV)
and residual error. BSV was assumed to be log-normally
distributed. The relationship between a pharmacokinetic
parameter (P) and its variance could therefore be expressed
as follows:
Pj ¼ PTV  egp
where Pj was the value of the pharmacokinetic parameter
for the jth individual, PTV was the typical value of P for the
population, and gp denoted the difference between Pj and
PTV, independently, which was identically distributed with
Fig. 1 Frequency histogram of the sampling distribution for concen-
tration measurements of the different compounds
Fig. 2 Spread of R,S-citalopram and R,S-desmethylcitalopram dose
normalized plasma concentration versus time after dose
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a mean of 0 and variance of x2. The residual variability
was composed of but not limited to experimental errors,
process noise, and/or model misspecification. This vari-
ability was modeled using additive, proportional and
combined structures.
Population and individual specific parameters were
determined in this analysis. Model parameters for both the
base model and the final model were estimated by the first-
order conditional estimation (FOCE) with interaction
method.
Final model
The final model was developed by evaluating the effect of
subject-specific covariates on pharmacokinetic parameter
estimates. Both continuous covariates (age, weight, and
BMI) and discrete covariates (CYP2C19 genotype, and
sex) were tested.
The effect of the continuous covariates on pharma-
cokinetic parameter estimates was tested using a centered
additive and power model. Age was centered on a value of
60 years, weight was centered on a value of 70 kg and BMI
was centered on a value of 25 lbs/in2.
With regard to the discrete covariates, the effect of sex
on pharmacokinetic parameter estimates was tested as
follows:
For sex : PTV ¼ h1p  sex
 þ ½h2p  ð1  sexÞ; sex
¼ 0 malesð Þ
or 1 femaleð Þ
where h1p was the corresponding parameter estimate for
females and h2p was for males. CYP2C19 genotype was
regrouped to have three possible values (EM/RM = 1, IM/
PM = 2 and missing = 3). The effect of CYP2C19
genotype on PK parameter estimates was tested as follows:
IF GEN ¼ 1 THENPTV ¼ h1p
IF GEN ¼ 2 THEN PTV ¼ h2p
IF GEN ¼ 3 THEN PTV ¼ h3p
where h1p was the corresponding parameter estimate for
EM/RM, h2p was for IM/PM, and h3p was for missing.
All covariates were incorporated into each parameter in
a stepwise fashion. The covariate was retained in the model
if the objective function value (OFV) decreased by 3.84.
The DOFV is assumed to be distributed according to a Chi
square distribution (v2); therefore for one degree of free-
dom a 3.84 difference in the OFV would be significant for a
p value level of 0.05. Goodness-of-fit plots were also used
as additional criteria during model development. A non-
parametric bootstrap was conducted with 100 replicates in
order to obtain uncertainty in the parameter estimates.
Results
Patient characteristics
Patient demographics and characteristics are summarized
in Table 1. Of the total 94 patients who provided concen-
tration samples, 81 participants data was included in the
population mixed effects pharmacokinetic analysis with 41
males (50.6 %) and 40 females (49.4 %). The average age
of the participants was 77.8 years with an average body
weight of 71.5 kg and average BMI of 26.3. Among all
patients the CYP2C19 frequencies for EM, RM, IM and
PM were 53.1, 3.7, 21, and 3.7 %. CYP2C19 genotypes
were missing for 18.5 % of patients.
Population pharmacokinetic modeling
The structure of the final model which best described the
pharmacokinetics of R,S-citalopram and their two primary
metabolites (R,S-desmethylcitalopram) in this patient
population consisted of four compartments (one for each
compound) with dosing into the parent compartments,
complete parent to metabolite conversion and linear
metabolite elimination (Fig. 3). The residual error was
separated with an additive structure for R-citalopram, a
proportional structure for R-desmethylcitalopram and both
S-citalopram and desmethylcitalopram. The oral absorption
rate constant was assumed to be equal for both enan-
tiomers. Both the parent and metabolite for the two
Table 1 Patient demographics and characteristics
Number of subjects 81
Total number of observations
R-citalopram 205 (2.5 observation/subject)
R-desmethylcitalopram 179 (2.2 observation/subject)
S-citalopram 205 (2.5 observation/subject)
S-desmethylcitalopram 109 (1.3 observation/subject)
Sex
Male 41 (50.6 %)
Female 40 (49.4 %)
Age, years, mean ± SD (range) 77.8 ± 8.2 (47–90)
Weight, kg, mean ± SD (range) 71.5 ± 17.2 (40–122.3)
Body mass index, lbs/in2,
mean ± SD (range)
26.3 ± 5.2 (15.4–41.6)
CYP2C19 genotype
Extensive metabolizers 43 (53.1 %)
Rapid metabolizers 3 (3.7 %)
Intermediate metabolizers 17 (21 %)
Poor metabolizers 3 (3.7 %)
Missing 15 (18.5 %)
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enantiomers were assumed to have the same volume of
distribution.
In the base model without any covariates added, the
estimated population apparent metabolic clearance was
8.6 L/h for R-citalopram and 14 L/h for S-citalopram.
R-desmethylcitalopram estimated population apparent
clearance was 23.8 L/h whereas S-desmethylcitalopram
estimated population apparent clearance was 38.5 L/h. The
estimated population apparent volume of distribution was
2050 L for R-citalopram and 1450 L for S-citalopram.
Several patient-specific covariates (age, sex, body
weight, and CYP2C19 genotype) had a significant effect on
different pharmacokinetic parameters. A centered power
model was chosen to model the effects of continuous
covariates (age and weight) on pharmacokinetic parameter
estimates. Final model development steps are listed in
Table 2. Diagnostic plots for the final model are shown in
Fig. 4. Additionally, diagnostic plots stratified by com-
pound are shown in supplementary Figs. 1, 2, 3, and 4
Estimates of the population pharmacokinetic parameters
from the full model along with the standard errors are listed
in Table 3. Uncertainty in parameter estimates was calcu-
lated by performing a nonparametric bootstrap.
The apparent metabolic clearance of R-citalopram was
approximately 30 % higher in males compared with female
patients (13 L/h for males and 9.05 L/h for females).
Additionally, there was a decrease in the apparent meta-
bolic clearance of R-citalopram with increased patient age.
This relationship was described in the final model by a
centered power function as follows: CLRp/F = CL0/
F 9 (Age/60)-0.822. Analysis of post-processed individual
empirical Bayes estimates showed that the apparent
metabolic clearance for R-citalopram in subjects aged
\70 years was 27.6 % faster than in subjects aged 70–79
and 43.5 % faster than in subjects aged 80–90 years. A
graphical representation of the relationship between the
empirical Bayes estimates of the apparent metabolic
Fig. 3 Final model compartmental structure
Table 2 Covariate selection for
final model
Model -2LL D -2LL df p valuea
Univariate forward selection
R-enantiomer Base 1465.08
CLRp Added age 1449.53 -15.55 1 8.03E-5
Added sex 1434.19 -15.34 1 8.99E-5
Full parent model ? base
metabolite model
2361.97
CLRm Added weight 2335.72 -26.25 1 3.00E-7
S-enantiomer Base 1330.84
LSp Added weight 1319.60 -11.24 1 8.00E-4
Added age 1310.87 -8.73 1 0.003
Added CYP2C19 genotype 1301.93 -8.94 2 0.01
Full parent model ? base
metabolite model
1743.85
CLSm Added weight 1721.89 -21.96 1 2.78E-6
Stepwise backward elimination
R,S-enantiomers Final model 4052.32
CLRp Removed age 4070.12 17.8 1 2.5E-5
Removed sex 4070.56 18.24 1 1.9E-5
CLRm Removed weight 4084.99 32.67 1 1.0E-8
CLSp Removed weight 4059.46 7.14 1 7.5E-3
Removed age 4067.82 15.5 1 8.3E-5
Removed CYP2C19 genotype 4061.49 9.17 2 0.01
CLSm Removed weight 4078.95 26.63 1 2.5E-7
a Calculated at 0.05 significance level
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clearance of R-citalopram with patient sex and age is
shown in Fig. 5. No significant effects of body weight,
BMI and CYP2C19 genotype were found on the apparent
metabolic clearance of R-citalopram.
Similarly the apparent metabolic clearance of S-citalo-
pram decreased with increased patient age. This was mod-
eled using a centered power function as follows: CLSp/
F = CL0/F 9 (Age/60)
-1.33. Analysis of post-processed
individual empirical Bayes estimates showed that the
apparent metabolic clearance for S-citalopram in subjects
aged \70 years was 49.1 % faster than in subjects aged
70–79 and 65.7 % faster than in subjects aged 80–90 years.
On the contrary, increased patient body weight resulted in an
increase in the apparent metabolic clearance of S-citalopram.
This relationship was also modeled by a centered power
function as follows: CLSp/F = CL0/F 9 (WT/70)
0.75.
Finally, CYP2C19 genotype was a significant factor in the
apparent metabolic clearance of S-citalopram. Patients who
were EM/RM had about 36 % higher apparent metabolic
clearance than those who were IM/PM. The estimated pop-
ulation apparent metabolic clearance of S-citalopram was
22.1 L/h for EM/RM, 16.3 L/h for IM/PM and 16.6 L/h for
subjects with missing CYP2C19 genotype. Figure 6 shows
the graphical representation of the relationship between the
apparent metabolic clearance of S-citalopram and the patient
specific covariates identified to be significant.
The apparent clearance of the two metabolites R,S-
desmethylcitalopram showed a significant relationship with
patient body weight modeled with a centered power func-
tion as follows: CLm/F = CL0/F 9 (WT/70)
0.75. Increased
body weight resulted in increased apparent metabolite
clearance. Post-processed individual empirical Bayes esti-
mates showed that the average apparent clearance of
R-desmethylcitalopram was 20.14 ± 5.26 L/h for patients
with body weights of \70 and 29.12 ± 9.95 L/h for
patients with body weights of C70 kg. The average
apparent clearance of S-desmethylcitalopram was
34.41 ± 5.78 L/h for patients with body weights of \70
and 46.22 ± 6.68 L/h for patients with body weights of
C70 kg. Figure 7 shows the relationship between the
metabolites apparent clearance and patient body weight in
a scatter plot. It is noteworthy to mention that final model
estimates showed that apparent clearance of S-desmethyl-
citalopram (38.8 L/h) was faster than R-desmethylcitalo-
pram (24.4 L/h).
Discussion
In this study, using a population approach, the population
pharmacokinetics of R,S-citalopram and their primary
metabolites (desmethylcitalopram) were successfully
Fig. 4 Diagnostic plots of the final pharmacokinetic model. a Population predicted versus observed concentrations. b Individual predicted versus
observed concentrations. c Conditional weighted residuals versus concentration. d Conditional weighted residuals versus time
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captured and described in elderly Alzheimer’s disease
patients who received citalopram for the treatment of agi-
tation. This analysis revealed that patient specific covari-
ates (body weight, age, sex and CYP2C19 genotype)
contributed differentially to the variability in the pharma-
cokinetic parameters of the two parent and metabolite
enantiomers. The findings of this analysis are in line with
several published studies that described the population
pharmacokinetics of citalopram [16, 17]. Additionally, the
results of our analysis are consistent with those derived
from studies with intensive sampling design [21] with an
s-citalopram apparent volume of distribution over 1000 L




median (95 % CI)
R-enantiomer
CLRp/F for male, L/h 13 13.8 (13.5–14.1) R-citalopram apparent metabolic clearance
CLRp/F for female, L/h 9.05 10.3 (10.1–10.5)
V/F, L 1830 1605 (1440–2090) R-citalopram apparent volume of distribution
Ka, h-1 1 (Fixed) NA Absorption rate constant
CLRm/F, L/h 24.4 23.5 (23.1–23.7) R-desmethylcitalopram apparent clearance
xCLp, % 26.38 28.7 (27.8–30) Variance of the BSV of R-citalopram apparent metabolic clearance
xV, % 166.73 107.2 (92.6–121.2) Variance of the BSV of R-enantiomer apparent volume of distribution
xCLm, % 30.61 34.9 (34.5–35.9) Variance of the BSV of R-desmethylcitalopram apparent clearance
r, ng/ml (additive) 13.42 13.6 (13.3–13.9) Variance of the residual error
r, % (proportional) 21.54 20.7 (20.4–21.3)
S-enantiomer
CLSp/F for EM/RM, L/h 22.1 21.9 (21.2–22.8) S-citalopram apparent metabolic clearance
CLSp/F for IM/PM, L/h 16.3 16.7 (15.9–17.2)
CLSp/F for Missing, L/h 16.8 17 (16.1–17.6)
V/F, L 1390 1310 (1130–1420) S-citalopram apparent volume of distribution
Ka, h-1 1 (Fixed) NA Absorption rate constant
CLSm/F, L/h 38.8 38.9 (38.4–39.2) S-desmethylcitalopram apparent clearance
xCLp, % 38.34 36.7 (35.8–38.5) Variance of the BSV of S-citalopram apparent metabolic clearance
xV, % 75.37 62.3 (59.5–68.9) Variance of the BSV of S-enantiomer apparent volume of distribution
xCLp;V, % 47.1 67 (54–82.7) Covariance of the BSV of S-citalopram apparent volume of
distribution and metabolic clearance
xCLm, % 20.49 20.1 (19.4–20.6) Variance of the BSV of S-desmethylcitalopram apparent clearance
r, % (proportional) 21.61 21.6 (21–22.1) Variance of the residual error
Fig. 5 R-citalopram metabolic clearance by patient a sex and b age (fitted line represents the relationship of clearance with age described by a
power model)
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and a half-life of up to 40 h (our analysis shows similar
apparent volume of distribution but higher overall half-life
of about 43 h in the EM/RM group in an older group of
psychiatric patients). It is noteworthy to mention that,
compared to previously published population PK analyses
for citalopram, this population analysis goes further by
Fig. 6 S-citalopram metabolic clearance by a CYP2C19 genotype, b age (fitted line represents the relationship of clearance with age described
by a power model) and c patient body weight (fitted line represents the linear relationship of clearance with weight)
Fig. 7 R-desmethylcitalopram (a) and S-desmethylcitalopram (b) clearance by body weight. Fitted lines represent the linear relationship of
metabolite clearance with weight
106 J Pharmacokinet Pharmacodyn (2016) 43:99–109
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delineating the pharmacokinetics for each enantiomer and
its primary metabolite.
Diagnostic plots of the final model showed good fitness
of the model to the observed data. The scatterplots of the
observed versus predicted population concentrations and
observed versus predicted individual concentrations were
distributed symmetrically around the line of unity. The
conditional weighted residuals were distributed symmetri-
cally around zero. No systematic shift in residuals was
evident from the plots of conditional weighted residual
versus predicted population concentrations or time after
dose.
Post-processed individual empirical Bayes estimates of
the two enantiomers showed that the average apparent
metabolic clearance of R-citalopram (8.73 ± 2.74 L/h) was
significantly slower than S-citalopram (13.76 ± 6.77 L/h)
(p\ 0.05, Mann–Whitney U test). Tanum et al. showed that
the plasma level of R-citalopram was significantly higher
than S-citalopram in patients receiving racemic citalopram
[22]. This difference was dose dependent and in the dose
group of (20–30 mg/daily, which is the dose range in our
analysis) the mean R/S ratio was 1.99. The difference in
apparent metabolic clearance of the enantiomers found in our
analysis may explain the observed difference in plasma
concentrations observed by Tanum et al. The individual
empirical Bayes estimates also showed that the average
apparent clearance of the R-desmethylcitalopram
(23.70 ± 9.05 L/h) was slower than S-desmethylcitalopram
(39.75 ± 8.74 L/h) (p\ 0.05, Mann–Whitney U test). In a
clinical study, it was shown that under steady-state condi-
tions the serum concentrations of S-desmethylcitalopram
represented 42 % of the total racemic serum concentrations
indicating faster clearance of the S-enantiomer which is
consistent with our finding [23].
The influence of sex on the pharmacokinetics of citalo-
pram has been controversial in the literature. Reis et al.
reported that women have lower citalopram clearance and
higher dose corrected citalopram plasma concentrations than
men [24, 25]. On the contrary, another study showed no
difference in dose corrected citalopram comparing men and
women [26]. A population pharmacokinetic analysis by Bies
et al. did not reveal an influence of sex on citalopram phar-
macokinetics [16]. Our analysis revealed a sex effect on the
apparent metabolic clearance of R-citalopram. No effect of
sex was found on S-citalopram or R,S-desmethylcitalopram
apparent clearance. Post-processed individual empirical
Bayes estimates showed that the average apparent metabolic
clearance for R-citalopram was 10.59 ± 2.41 L/h (males)
and 7.25 ± 1.87 L/h (females). This finding could explain
the conflicting reports in the literature with regard to the sex
effect on citalopram PK. Since citalopram is administered as
50/50 racemic mixture it is difficult to capture the sex dif-
ferences on each enantiomer PK without having separate
measurement of the two enantiomer or by conducting a tra-
ditional PK analysis. Given the measurement of each enan-
tiomer and by using a population level approach (accounting
for fixed and random effects), our analysis provided the
opportunity to understand the influence of sex on the overall
citalopram PK by showing that this effect is on the R-ci-
talopram metabolic clearance only. This observation may
have implications for assessing the differential impact of the
two enantiomers on clinical outcomes. Ho et al. showed that
R-citalopram exposure (represented by area under the curve
AUC) was mainly responsible for the QTc prolongation and
negative impact on cognition (Mini-Mental State Examina-
tion score). Moreover higher R-citalopram AUC was asso-
ciated with the probability of worse patient response to
treatment as compared to placebo [27]. The differences in the
patient specific factors affecting the R- and S-enantiomers of
citalopram suggest the potential for within-individual dif-
ferences in the R and S enantiomer concentrations that could
contribute to different responses attributable to these
enantiomers.
Model results showed a decrease in the apparent meta-
bolic clearance of R,S-citalopram with increasing age. This
finding is in agreement with previously published popula-
tion models. In a population analysis of S-citalopram, the
mean clearance for subjects aged 50–65 years was
21.74 L/h [17]. Our analysis showed that the apparent
metabolic clearance of S-citalopram for similar age group
(47–68 years) was 22.63 L/h. So even though more than
85 % of subjects in our analysis are elderly (C70 years)
our model prediction of S-citalopram apparent metabolic
clearance in younger subjects was very similar with pre-
vious published findings.
In addition to age, our model revealed that the apparent
metabolic clearance of S-citalopram was influenced by
weight and CYP2C19 genotype. This has been captured
and described previously by Jin et al. [17]. In that study
EM/RM subjects were reported to have a 33.7 % faster
S-citalopram clearance than IM/PM. Despite the fact that
the studied population in our study is older than the one in
Jin et al. study, our analysis showed that EM/RM subjects
had a 25.6 % faster apparent metabolic clearance of S-ci-
talopram than IM/PM subjects. No impact of CYP2C19
genotype was observed in our analysis on the apparent
metabolic clearance of R-citalopram. In a study by Herrlin
et al. the impact of CYP2C19/CYP2D6 on the metabolism
of R,S-citalopram was evaluated [28]. Results showed no
impact of genotype on the exposure (i.e. AUC) of R-ci-
talopram. Other studies that have assessed the impact of
CYP2C19 genotype on racemic citalopram reported sig-
nificant differences in exposure or disposition of citalo-
pram due to CYP2C19 genotype [29–31]. Our findings
suggest that those observed differences may be attributed
to the impact of CYP2C19 genotype on S-citalopram only.
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As mentioned previously, our analysis showed that the
overall apparent clearance of the R-enantiomer was slower
than that of the S-enantiomer. Additionally, there was a
further decline in the apparent metabolic clearance of
R-citalopram in females. All leads to the assumption that
exposure to R-citalopram in this patient population would
be higher than S-citalopram. Post-processed individual
empirical Bayes estimates showed that exposure (AUC) to
R-citalopram (1.46 ± 0.58 mg/L/h) was significantly
higher than that of S-citalopram (0.97 ± 0.45 mg/L/h)
(p\ 0.05, Mann–Whitney U test). Published studies sug-
gested that R-citalopram antagonizes or counteracts S-ci-
talopram activity [32–36]. Taken together, the findings of
our study suggest that it may be warranted to evaluate
S-citalopram (escitalopram) for treatment for the manage-
ment of agitation in elderly patients with AD.
One caveat in this analysis is that both enantiomers are
administered simultaneously in one pill containing the
racemic citalopram. Hence we cannot determine the impact
of this co-administration on the pharmacokinetics of each
enantiomer. Ideally, a separate administration of the
S-enantiomer would allow for a comparison with the racemic
drug administration. In such case a clearer understanding of
the pharmacokinetics/pharmacodynamics relationship
would be feasible. That being said, there are sufficient dif-
ferences within individuals in the R- and S-citalopram
enantiomer disposition that they are not perfectly correlated
and would allow for the exploration of enantiomer specific
effects on observed responses. On the other hand, clearance
was shown in this analysis to be the driver behind the dif-
ference in exposure to the R- versus S-enantiomer. It is
noteworthy to mention bioavailability in this analysis was
not explored as IV administration and oral of the individual
enantiomers was not part of the study design and therefore
the bioavailability could not be determined. Hence it is safe
to assume that the observed differences in exposure of the
two enantiomers may be related to underlying differences in
bioavailability. There are no reports of bioavailability of
R-citalopram however reported bioavailability for racemic
citalopram and S-citalopram is 80 % [21]. Finally, although
our model structure assumes complete parent to metabolite
conversion, it is important to note that a small portion of
citalopram is excreted in the urine unchanged (8–10 % in the
case of S-citalopram) [21]. With more intensive sampling
(i.e. collection of urine samples) the model could be refined
to reflect urinary excretion.
Conclusions
The findings of this study was able to delineate between the
pharmacokinetics of R versus S-citalopram and -desmethyl-
citalopram in elderly patient population. We have identified a
differential influence of some patient specific covariates on
the pharmacokinetics of both enantiomers and their primary
metabolite, all of which have implications on understanding
the pharmacokinetic/pharmacodynamics relationship in order
to optimize therapy and tailor it to the needs of the patient. In
particular, the potential for higher exposure of R-citalopram in
women may increase the possibility of untoward cognitive
impacts but this will need to be studied specifically using
escitalopram to confirm.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creative
commons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Ballard C, Corbett A (2013) Agitation and aggression in people
with Alzheimer’s disease. Curr Opin Psychiatry 26(3):252–259.
doi:10.1097/YCO.0b013e32835f414b
2. Ackerman K, Dimartini A (2015) Psychosomatic medicine.
Oxford University Press
3. Kalore AN, Medappa D, Ranjit E, Nayak ES (2015) Safety and
efficacy of pharmacological management of agitation in Alzhei-
mer’s dementia - a review. Int J Health Rehabil Sci 4(1):65–72
4. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis
C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA,
Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM,
Weintraub D, Yesavage J, Lyketsos CG, Cit ADRG (2014) Effect
of citalopram on agitation in Alzheimer disease: the CitAD ran-
domized clinical trial. JAMA 311(7):682–691. doi:10.1001/jama.
2014.93
5. Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C,
Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG,
Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade
DM, Weintraub D, Yesavage J, Lyketsos CG, Cit ADRG (2014)
Changes in QTc interval in the citalopram for agitation in Alz-
heimer’s disease (CitAD) randomized trial. PLoS ONE
9(6):e98426. doi:10.1371/journal.pone.0098426
6. Hyttel J, Bøgesø KP, Perregaard J, Sa´nchez C (1992) The phar-
macological effect of citalopram resides in the (S)-(?)-enan-
tiomer. J Neural Transmission 88(2):157–160. doi:10.1007/
BF01244820
7. Sa´nchez C, Bergqvist PBF, Brennum LT, Gupta S, Hogg S,
Larsen A, Wiborg O (2003) Escitalopram, the S-(?)-enantiomer
of citalopram, is a selective serotonin reuptake inhibitor with
potent effects in animal models predictive of antidepressant and
anxiolytic activities. Psychopharmacology 167(4):353–362.
doi:10.1007/s00213-002-1364-z
8. Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G,
Signoretti A, Churchill R, Watanabe N, Barbui C (2012)
Citalopram versus other anti-depressive agents for depression.
Cochrane Database Syst Rev 7:CD006534. doi:10.1002/
14651858.CD006534.pub2
9. Pastoor D, Gobburu J (2014) Clinical pharmacology review of esc-
italopram for the treatment of depression. Expert Opin Drug Metab
Toxicol 10(1):121–128. doi:10.1517/17425255.2014.863873
10. Colonna L, Andersen HF, Reines EH (2005) A randomized,
double-blind, 24-week study of escitalopram (10 mg/day) versus
108 J Pharmacokinet Pharmacodyn (2016) 43:99–109
123
citalopram (20 mg/day) in primary care patients with major
depressive disorder. Curr Med Res Opin 21(10):1659–1668.
doi:10.1185/030079905X65484
11. Gorman JM, Korotzer A, Su G (2002) Efficacy comparison of
escitalopram and citalopram in the treatment of major depressive
disorder: pooled analysis of placebo-controlled trials. CNS Spectr
7(4 Suppl 1):40–44
12. Schatzberg AF, Nemeroff CB (2013) Essentials of clinical psy-
chopharmacology. American Psychiatric Pub
13. Pollock BG (2001) Citalopram: a comprehensive review. Expert
Opin Pharmacother 2(4):681–698. doi:10.1517/14656566.2.4.681
14. Fredericson Overø K, Toft B, Christophersen L, Gylding-Sabroe
JP (1985) Kinetics of citalopram in elderly patients. Psy-
chopharmacology 86(3):253–257. doi:10.1007/BF00432209
15. Gutierrez M, Abramowitz W (2000) Steady-state pharmacoki-
netics of citalopram in young and elderly subjects. Pharma-
cotherapy J Human Pharm Drug Ther 20(12):1441–1447. doi:10.
1592/phco.20.19.1441.34851
16. Bies RR, Feng Y, Lotrich FE, Kirshner MA, Roose S, Kupfer DJ,
Pollock BG (2004) Utility of sparse concentration sampling for
citalopram in elderly clinical trial subjects. J Clin Pharmacol
44(12):1352–1359. doi:10.1177/0091270004269647
17. Jin Y, Pollock BG, Frank E, Cassano GB, Rucci P, Muller DJ,
Kennedy JL, Forgione RN, Kirshner M, Kepple G, Fagiolini A,
Kupfer DJ, Bies RR (2010) Effect of age, weight, and CYP2C19
genotype on escitalopram exposure. J Clin Pharmacol
50(1):62–72. doi:10.1177/0091270009337946
18. Duffull SB, Wright DF, Winter HR (2011) Interpreting popula-
tion pharmacokinetic-pharmacodynamic analyses - a clinical
viewpoint. Br J Clin Pharmacol 71(6):807–814. doi:10.1111/j.
1365-2125.2010.03891.x
19. Rocha A, Marques MP, Coelho EB, Lanchote VL (2007) Enan-
tioselective analysis of citalopram and demethylcitalopram in
human and rat plasma by chiral LC-MS/MS: application to
pharmacokinetics. Chirality 19(10):793–801. doi:10.1002/chir.
20452
20. Foglia JP, Pollock BG, Kirshner MA, Rosen J, Sweet R, Mulsant
B (1997) Plasma levels of citalopram enantiomers and metabo-
lites in elderly patients. Psychopharmacol Bull 33(1):109–112
21. Rao N (2007) The clinical pharmacokinetics of escitalopram.
Clin Pharmacokinet 46(4):281–290
22. Tanum L, Strand LP, Refsum H (2010) Serum concentrations of
citalopram - dose-dependent variation in R- and S-enantiomer
ratios. Pharmacopsychiatry 43(5):190–193. doi:10.1055/s-0030-
1254106
23. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen
F (1997) Steady-state pharmacokinetics of the enantiomers of
citalopram and its metabolites in humans. Chirality 9(7):686–692.
doi:10.1002/(SICI)1520-636X(1997).9:7\686:AID-CHIR9[3.0.
CO;2-5
24. Reis M, Lundmark J, Bengtsson F (2003) Therapeutic drug
monitoring of racemic citalopram: a 5-year experience in Swe-
den, 1992–1997. Ther Drug Monit 25(2):183–191
25. Reis M, Olsson G, Carlsson B, Lundmark J, Dahl ML, Walinder
J, Ahlner J, Bengtsson F (2002) Serum levels of citalopram and
its main metabolites in adolescent patients treated in a naturalistic
clinical setting. J Clin Psychopharmacol 22(4):406–413
26. de Mendonca Lima CA, Baumann P, Brawand-Amey M, Brogli
C, Jacquet S, Cochard N, Powell-Golay K, Eap CB (2005) Effect
of age and gender on citalopram and desmethylcitalopram steady-
state plasma concentrations in adults and elderly depressed
patients. Prog Neuro-Psychopharmacol Biol Psychiatry 29(6):952
–956. doi:10.1016/j.pnpbp.2005.06.001
27. Ho T, Bies R, Mulsant BH, Devanand DP, Mintzer J, Por-
steinsson A, Schneider DW, Yesavage J, Drye LT, Munro CA,
Shade DM, Lyketsos C, Pollock BG (2015) Effect of treatment
time and citalopram enantiomer levels on agitation and QTc
interval in patients with Alzheimer disease. In: American
Pyschaitric Association Annual Meeting Toronto, Canada
28. Herrlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson
LL, Bertilsson L (2003) Metabolism of citalopram enantiomers in
CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J
Clin Pharmacol 56(4):415–421
29. Chang M, Tybring G, Dahl ML, Lindh JD (2014) Impact of
cytochrome P450 2C19 polymorphisms on citalopram/escitalo-
pram exposure: a systematic review and meta-analysis. Clin
Pharmacokinet 53(9):801–811. doi:10.1007/s40262-014-0162-1
30. Fudio S, Borobia AM, Pinana E, Ramirez E, Tabares B, Guerra P,
Carcas A, Frias J (2010) Evaluation of the influence of sex and
CYP2C19 and CYP2D6 polymorphisms in the disposition of
citalopram. Eur J Pharmacol 626(2–3):200–204. doi:10.1016/j.
ejphar.2009.10.007
31. Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou
HH (2003) Pharmacokinetics of citalopram in relation to genetic
polymorphism of CYP2C19. Drug Metab Dispos
31(10):1255–1259. doi:10.1124/dmd.31.10.1255
32. Sanchez C (2006) The pharmacology of citalopram enantiomers:
the antagonism by R-citalopram on the effect of S-citalopram.
Basic Clin Pharmacol Toxicol 99(2):91–95. doi:10.1111/j.1742-
7843.2006.pto_295.x
33. Sanchez C, Kreilgaard M (2004) R-citalopram inhibits functional
and 5-HTP-evoked behavioural responses to the SSRI, escitalo-
pram. Pharmacol Biochem Behav 77(2):391–398
34. Sanchez C, Gruca P, Papp M (2003) R-citalopram counteracts the
antidepressant-like effect of escitalopram in a rat chronic mild
stress model. Behav Pharmacol 14(5–6):465–470. doi:10.1097/
01.fbp.0000087733.21047.60
35. Sanchez C, Gruca P, Bien E, Papp M (2003) R-citalopram
counteracts the effect of escitalopram in a rat conditioned fear
stress model of anxiety. Pharmacol Biochem Behav 75(4):
903–907
36. Storustovu S, Sanchez C, Porzgen P, Brennum LT, Larsen AK,
Pulis M, Ebert B (2004) R-citalopram functionally antagonises
escitalopram in vivo and in vitro: evidence for kinetic interaction
at the serotonin transporter. Br J Pharmacol 142(1):172–180.
doi:10.1038/sj.bjp.0705738
J Pharmacokinet Pharmacodyn (2016) 43:99–109 109
123
